drugset / Trial / NCT00199888

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

NCT00199888

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.

Timeline

Start
2005-06
Primary completion
2006-03
Completion
2009-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject girentuximab Monoclonal antibody 10 mg Intravenous
Subject girentuximab Monoclonal antibody 185 mbq Intravenous